SAN DIEGO , April 24, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on April 15, 2020 , the Compensation Committee of its Board of Directors granted inducement stock options to purchase an aggregate of 39,800 shares of its common stock to nine new employees
SAN DIEGO , April 10, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , the Company's President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the 19th Annual Needham Healthcare Conference on Tuesday, April
- Etrasimod CR profile designed to retain etrasimod's rapid onset of action while further improving its potentially best-in-class, non-titrated, low intrinsic first-dose heart rate effect - Positive topline data from Phase 1 study demonstrated significant reduction in heart rate effect,
SAN DIEGO , March 30, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that James C. Mullen has agreed to serve as an independent senior advisor to the Company. "We are honored to have Jim as an advisor to Arena. In a rapidly evolving industry, and especially in
SAN DIEGO , March 18, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on March 12, 2020 , the Compensation Committee of its Board of Directors approved inducement stock options and inducement performance restricted stock units ("PRSUs") to new employees that
SAN DIEGO , Feb. 21, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on February 10, 2020 the Compensation Committee of its Board of Directors granted inducement stock options to purchase an aggregate of 132,100 shares of its common stock to 20 new employees.
SAN DIEGO , Feb. 20, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , President and Chief Executive Officer, will present at the upcoming investor conferences: SVB Leerink 9th Annual Global Healthcare Conference – Presenting on Tuesday, February
- New biomarker data from the open-label extension (OLE) of the Phase 2 OASIS trial for etrasimod in patients with moderately to severely active ulcerative colitis (UC) - Arena sponsored dinner symposium: HYPE, HOPE or REALITY? Integrating histology into a treat-to-target strategy in UC, with
- APD418 currently in Phase 1 clinical investigation - data expected this year SAN DIEGO , Jan. 16, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the U.S. Food and Drug Administration ( FDA ) granted Fast Track designation for APD418, a β 3 -adrenergic
SAN DIEGO , Jan. 13, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the appointment of Joan Schmidt as Executive Vice President, General Counsel and Secretary. Ms. Schmidt will join Arena formally in March 2020 and report to Amit D.